Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,604 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Transcatheter Mitral-Valve Repair in Patients with Heart Failure.
Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, Whisenant B, Grayburn PA, Rinaldi M, Kapadia SR, Rajagopal V, Sarembock IJ, Brieke A, Marx SO, Cohen DJ, Weissman NJ, Mack MJ; COAPT Investigators. Stone GW, et al. Among authors: cohen dj. N Engl J Med. 2018 Dec 13;379(24):2307-2318. doi: 10.1056/NEJMoa1806640. Epub 2018 Sep 23. N Engl J Med. 2018. PMID: 30280640 Clinical Trial.
Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial.
Stone GW, Moliterno DJ, Bertrand M, Neumann FJ, Herrmann HC, Powers ER, Grines CL, Moses JW, Cohen DJ, Cohen EA, Cohen M, Wolski K, DiBattiste PM, Topol EJ. Stone GW, et al. Among authors: cohen dj, cohen ea, cohen m. Circulation. 2002 May 21;105(20):2347-54. doi: 10.1161/01.cir.0000017635.82128.8c. Circulation. 2002. PMID: 12021219 Clinical Trial.
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.
Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ; REPLACE-2 Investigators. Lincoff AM, et al. Among authors: cohen dj, cohen ea. JAMA. 2003 Feb 19;289(7):853-63. doi: 10.1001/jama.289.7.853. JAMA. 2003. PMID: 12588269 Clinical Trial.
Effect of abciximab versus tirofiban on activated clotting time during percutaneous intervention and its relation to clinical outcomes--observations from the TARGET trial.
Casserly IP, Topol EJ, Jia G, Lange RA, Hamm C, Meier B, DiBattiste PM, Lakkis N, Chew DP, Stone GW, Cohen DJ, Moliterno DJ. Casserly IP, et al. Among authors: cohen dj. Am J Cardiol. 2003 Jul 15;92(2):125-9. doi: 10.1016/s0002-9149(03)00525-3. Am J Cardiol. 2003. PMID: 12860211 Clinical Trial.
Outcomes of optimal or "stent-like"balloon angioplasty in acutemyocardial infarction: the CADILLAC trial.
Cox DA, Stone GW, Grines CL, Stuckey T, Cohen DJ, Tcheng JE, Garcia E, Guagliumi G, Iwaoka RS, Fahy M, Turco M, Lansky AJ, Griffin JJ, Mehran R; CADILLAC Investigators. Cox DA, et al. Among authors: cohen dj. J Am Coll Cardiol. 2003 Sep 17;42(6):971-7. doi: 10.1016/s0735-1097(03)00911-2. J Am Coll Cardiol. 2003. PMID: 13678914 Free article. Clinical Trial.
Importance of mitral regurgitation inpatients undergoing percutaneous coronary intervention for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
Pellizzon GG, Grines CL, Cox DA, Stuckey T, Tcheng JE, Garcia E, Guagliumi G, Turco M, Lansky AJ, Griffin JJ, Cohen DJ, Aymong E, Mehran R, O'Neill WW, Stone GW. Pellizzon GG, et al. Among authors: cohen dj. J Am Coll Cardiol. 2004 Apr 21;43(8):1368-74. doi: 10.1016/j.jacc.2003.11.046. J Am Coll Cardiol. 2004. PMID: 15093869 Free article. Clinical Trial.
Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial.
Lincoff AM, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ; REPLACE-2 Investigators. Lincoff AM, et al. Among authors: cohen dj, cohen ea. JAMA. 2004 Aug 11;292(6):696-703. doi: 10.1001/jama.292.6.696. JAMA. 2004. PMID: 15304466 Clinical Trial.
Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial.
Cohen DJ, Lincoff AM, Lavelle TA, Chen HL, Bakhai A, Berezin RH, Jackman D, Sarembock IJ, Topol EJ. Cohen DJ, et al. J Am Coll Cardiol. 2004 Nov 2;44(9):1792-800. doi: 10.1016/j.jacc.2004.05.085. J Am Coll Cardiol. 2004. PMID: 15519009 Free article. Clinical Trial.
Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial.
Rajagopal V, Lincoff AM, Cohen DJ, Gurm HS, Hu T, Desmet WJ, Kleiman NS, Bittl JA, Feit F, Topol EJ. Rajagopal V, et al. Among authors: cohen dj. Am Heart J. 2006 Jul;152(1):149-54. doi: 10.1016/j.ahj.2005.09.007. Am Heart J. 2006. PMID: 16824845
1,604 results